Education
About Us
Working with TipRanks
Follow Us
Novabridge Biosciences (NBP)
NASDAQ:NBP
NBP Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
NovaBridge Biosciences News
NBP FAQ
What was Novabridge Biosciences’s price range in the past 12 months?
Novabridge Biosciences lowest stock price was $0.59 and its highest was $6.79 in the past 12 months.
What is Novabridge Biosciences’s market cap?
Novabridge Biosciences’s market cap is $518.81M.
When is Novabridge Biosciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Novabridge Biosciences’s earnings last quarter?
Currently, no data Available
Is Novabridge Biosciences overvalued?
According to Wall Street analysts Novabridge Biosciences’s price is currently Undervalued.
Does Novabridge Biosciences pay dividends?
Novabridge Biosciences does not currently pay dividends.
What is Novabridge Biosciences’s EPS estimate?
Novabridge Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novabridge Biosciences have?
Novabridge Biosciences has 115,119,490 shares outstanding.
What happened to Novabridge Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Novabridge Biosciences?
Currently, no hedge funds are holding shares in NBP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovaBridge Biosciences Stock Smart Score
Company Description
Novabridge Biosciences
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Ownership Overview
―
Insiders
0.06%
Mutual Funds
14.61% Other Institutional Investors
84.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---